This website is intended for healthcare professionals only
User log in




Trial log in
  

Tailoring therapy to the individual patient


This module has been initiated, funded and reviewed by Boehringer Ingelheim. The content of this industry-supported learning activity has been generated by Practice Nurse.

INTRODUCTION

The goals of therapy for type 2 diabetes are to prevent or delay complications and maintain quality of life. This requires control of glycaemia, management of cardiovascular risk factors, regular follow-up and importantly a patient centred approach.1 This is in line with the Nursing and Midwifery Council (NMC) Code, which says that nurses should ‘prioritise people, practise effectively, preserve safety and promote professionalism and trust’.2 In addition, National Institute for Health and Care Excellence (NICE) guidelines emphasise the importance of taking into account individual needs and preferences.3

LEARNING OBJECTIVES

On completion of this module, the general practice nurse will:

  • Be familiar with the importance of providing individualised diabetes care
  • Be able to take account of the individual patient’s needs in the choice of treatment
  • Understand some of the key considerations when selecting treatment for the individual with type 2 diabetes, including cardiovascular and renal risk, undesirable effects such as hypoglycaemia or weight gain, and the implications of frailty and older age
  • Understand how to use the guideline recommendations in a holistic approach to the care of patients with diabetes.

This module is one of a series of five. Others in the series are:

  • Targets for glycaemic control in type 2 diabetes
  • Short-term complications of type 2 diabetes
  • Renal considerations in patients with type 2 diabetes
  • Cardiovascular considerations in patients with type 2 diabetes

This resource is provided at an intermediate level. Read the article and answer the self-assessment questions, and reflect on what you have learned.

Complete the resource to obtain a certificate to include in your revalidation portfolio. You should record the time spent on this resource in your CPD log.

Job Code: PC-GB-102834

Date of preparation: January 2021


You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI's products, services and events.

Click here for Trajenta (linagliptin) Prescribing Information

Click here for Jardiance (empagliflozin) Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).